Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity

Simple item page
dc.contributor.authorViljoen, M
dc.date.accessioned2023-03-22T09:38:35Z
dc.date.available2023-03-22T09:38:35Z
dc.date.issued2022
dc.description.abstractObjective: Doxorubicin is a valuable chemotherapeutic drug; however, it is associated with a high risk of cardiotoxicity. Several institutions and organizations have developed guidelines for risk factor assessment, monitoring, and prevention strategies against chemotherapy-induced cardiotoxicity. This review aimed to assess the quality of current practice guidelines, using the Appraisal of Guidelines for Research and Evaluation II (AGREE II). This tool was used to compare the recommendations with regards to their strength and the evidence recommendations were based on.en_US
dc.identifier.citationMoustafa, I., Viljoen, M., Perumal-Pillay, V. A., & Oosthuizen, F. (2022). Critical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicity. Journal of Oncology Pharmacy Practice, 107815522211476. https://doi.org/10.1177/10781552221147660en_US
dc.identifier.issn1078-1552, 1477-092X
dc.identifier.urihttp://hdl.handle.net/10566/8631
dc.language.isoenen_US
dc.publisherJournal of Oncology Pharmacy Practiceen_US
dc.subjectdoxorubicinen_US
dc.subjectassessmenten_US
dc.subjectmonitoringen_US
dc.subjectmanagementen_US
dc.subjectguidelineen_US
dc.titleCritical appraisal of clinical guidelines for prevention and management of doxorubicin-induced cardiotoxicityen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Viljoen_critical_appraisal_of_clinical_guidelines_2022.pdf
Size:
691.54 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Research Articles (School of Pharmacy)